Benson Investment Management Company Inc. Buys New Shares in Novo Nordisk A/S (NYSE:NVO)

Benson Investment Management Company Inc. bought a new position in shares of Novo Nordisk A/S (NYSE:NVO - Free Report) during the 1st quarter, according to its most recent 13F filing with the SEC. The firm bought 65,019 shares of the company's stock, valued at approximately $4,515,000. Novo Nordisk A/S accounts for approximately 2.0% of Benson Investment Management Company Inc.'s holdings, making the stock its 27th largest position.

A number of other institutional investors have also recently bought and sold shares of NVO. M. Kulyk & Associates LLC boosted its stake in Novo Nordisk A/S by 3.9% in the 4th quarter. M. Kulyk & Associates LLC now owns 3,182 shares of the company's stock worth $274,000 after purchasing an additional 119 shares during the period. Center for Financial Planning Inc. grew its holdings in Novo Nordisk A/S by 72.4% during the fourth quarter. Center for Financial Planning Inc. now owns 293 shares of the company's stock worth $25,000 after purchasing an additional 123 shares during the period. Tradewinds Capital Management LLC raised its stake in Novo Nordisk A/S by 2.6% in the 4th quarter. Tradewinds Capital Management LLC now owns 4,984 shares of the company's stock valued at $429,000 after acquiring an additional 124 shares during the period. Exencial Wealth Advisors LLC raised its position in shares of Novo Nordisk A/S by 0.5% in the fourth quarter. Exencial Wealth Advisors LLC now owns 23,094 shares of the company's stock valued at $1,987,000 after purchasing an additional 124 shares during the period. Finally, Indie Asset Partners LLC lifted its position in Novo Nordisk A/S by 4.2% during the fourth quarter. Indie Asset Partners LLC now owns 3,128 shares of the company's stock worth $269,000 after acquiring an additional 126 shares during the last quarter. Institutional investors own 11.54% of the company's stock.

Analyst Ratings Changes

NVO has been the topic of a number of analyst reports. Hsbc Global Res upgraded shares of Novo Nordisk A/S to a "strong-buy" rating in a research report on Monday, April 28th. BNP Paribas began coverage on shares of Novo Nordisk A/S in a research report on Tuesday, April 15th. They set an "underperform" rating on the stock. Guggenheim cut shares of Novo Nordisk A/S from a "strong-buy" rating to a "hold" rating in a research note on Thursday, April 17th. Stifel Nicolaus cut Novo Nordisk A/S from a "buy" rating to a "hold" rating in a research note on Monday, March 3rd. Finally, Morgan Stanley initiated coverage on Novo Nordisk A/S in a research note on Wednesday, February 12th. They issued an "equal weight" rating on the stock. Two analysts have rated the stock with a sell rating, five have issued a hold rating, four have given a buy rating and two have assigned a strong buy rating to the company. Based on data from MarketBeat, Novo Nordisk A/S currently has an average rating of "Hold" and an average price target of $128.00.

Novo Nordisk A/S Trading Up 0.7%

NYSE:NVO traded up $0.53 during trading hours on Thursday, hitting $72.57. 5,088,580 shares of the company were exchanged, compared to its average volume of 6,858,486. Novo Nordisk A/S has a one year low of $57.00 and a one year high of $148.15. The company has a current ratio of 0.74, a quick ratio of 0.55 and a debt-to-equity ratio of 0.62. The stock has a market capitalization of $325.64 billion, a price-to-earnings ratio of 22.06, a price-to-earnings-growth ratio of 0.90 and a beta of 0.66. The company has a fifty day simple moving average of $65.67 and a 200 day simple moving average of $81.09.

Novo Nordisk A/S (NYSE:NVO - Get Free Report) last released its earnings results on Wednesday, May 7th. The company reported $0.92 earnings per share for the quarter, meeting analysts' consensus estimates of $0.92. The business had revenue of $11.87 billion during the quarter. Novo Nordisk A/S had a net margin of 34.81% and a return on equity of 84.68%. Sell-side analysts expect that Novo Nordisk A/S will post 3.84 EPS for the current fiscal year.

About Novo Nordisk A/S

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.